<DOC>
	<DOCNO>NCT00186979</DOCNO>
	<brief_summary>The purpose protocol estimate maximum tolerate dose gefitinib combination fix dose irinotecan vincristine patient refractory solid tumor .</brief_summary>
	<brief_title>Study ZD1839 Combined With Irinotecan Vincristine Pediatric Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>Objectives study : - To determine dose-limiting toxicity ( DLT ) combination irinotecan ZD1839 give schedule . - To characterize pharmacokinetics pharmacodynamics gefitinib alone combination irinotecan vincristine . - To estimate maximum tolerate dose ( MTD ) gefitinib combination escalate intravenous irinotecan use selective intestinal decontamination oral cefixime cefpodoxime prevent diarrhea . - To estimate MTD vincristine ( MTD ) combination gefitinib irinotecan . Details Treatment Interventions First Cohort : Standard dose escalation , start ZD1839 150 mg/m2/day 21 day combination irinotecan 15mg/m2/day daily x 5 two consecutive week schedule . Dose-limiting diarrhea see cohort . ZD schedule reduce 12 day . The first dose level ( 1a ) consist ZD1839 112.5mg/m2/day 12 day + irinotecan 15mg/m2/day daily x 5 x 2 find MTD cohort . Second Cohort : Cefixime add 4 additional subject enrol dose level 1c , consist ZD1839 112mg/m2/day + irinotecan 20mg/m2/day + cefixime 8 mg/kg/day administer daily , begin day -1 , continue day 14 . Third Cohort : Irinotecan/ZD1839/Vincristine/Cefixime- Cefixime 8 mg/kg/day administer daily , begin day -1 , continue day 14 , maximum dose 400 mg daily + gefitinib 112.5 mg/m2 orally , daily 12 day irinotecan 15 mg/m2 daily x 5 x 2 +1 mg/m2 ( maximum 2mg/dose ) day 1 8 escalate dose VCR tolerate .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cefpodoxime</mesh_term>
	<mesh_term>Cefixime</mesh_term>
	<criteria>Younger 22 year age . Histologic verification solid tumor malignancy original diagnosis . Has disease consider refractory conventional therapy conventional therapy exists . Adequate performance status , bone marrow , liver kidney function . Patients must previous allergic reaction penicillin cephalosporin Known severe hypersensitivity ZD1839 excipients product Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital , St John 's Wort , CYP3A4 inhibitor Treatment nonapproved investigational drug within 30 day Day 1 trial treatment . Incomplete heal previous oncologic major surgery Pregnant breastfeeding Patients uncontrolled infection Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude ) . As judged investigator , evidence uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) . Evidence significant clinical disorder laboratory find make undesirable subject participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Refractory Childhood Solid Tumors</keyword>
</DOC>